initiated Phase III trials (12/08); sub-analysis from Phase IIb data gives insight into reduced bleeding with once-daily dosing (7/09); initiated new large-scale pivotal Phase III trial looking at reducing recurrent VTE complications in patients with DVT and/or PE (2/10); JNDA submitted in Japan (4/10)
Brand N/A Generic edoxaban (DU-176b)
Company name Daiichi Sankyo Product type Speciality
Therapeutic category Cardiovascular agents Key uses Atrial fibrillation
Other Uses treatment of VTE, prevention of DVT after major orthopaedic surgery Drug Class Factor Xa inhibitor, anticoagulant
Dosage From oral Expected Approval 2012+
FDA Filing N/A Last Update date June 02,2010
Link to pipeline report
Link to news article
Link to clinicaltrials.gov